KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBITDA (2016 - 2025)

Historic EBITDA for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $300.0 million.

  • Teva Pharmaceutical Industries' EBITDA rose 113448.28% to $300.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 81155.12%. This contributed to the annual value of $2.2 billion for FY2025, which is 81188.12% up from last year.
  • Teva Pharmaceutical Industries' EBITDA amounted to $300.0 million in Q4 2025, which was up 113448.28% from $882.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBITDA registered a high of $882.0 million during Q3 2025, and its lowest value of -$967.0 million during Q2 2022.
  • Moreover, its 5-year median value for EBITDA was $189.0 million (2021), whereas its average is $90.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 157692.31% in 2024, then soared by 920000.0% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBITDA stood at $78.0 million in 2021, then plummeted by 1305.13% to -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then crashed by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025.
  • Its EBITDA stands at $300.0 million for Q4 2025, versus $882.0 million for Q3 2025 and $455.0 million for Q2 2025.